Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent
PURPOSE: To evaluate the time-dependent changes in regional quantitative T2* maps of the kidney following intravenous administration of ferumoxytol. MATERIALS AND METHODS: Twenty-four individuals with normal kidney function underwent T2*-weighted MRI of the kidney before, immediately after, and 48 h...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010631/ https://www.ncbi.nlm.nih.gov/pubmed/24812510 http://dx.doi.org/10.2147/IJN.S61460 |
_version_ | 1782479885811318784 |
---|---|
author | Hedgire, Sandeep S McDermott, Shaunagh Wojtkiewicz, Gregory R Abtahi, Seyed Mahdi Harisinghani, Mukesh Gaglia, Jason L |
author_facet | Hedgire, Sandeep S McDermott, Shaunagh Wojtkiewicz, Gregory R Abtahi, Seyed Mahdi Harisinghani, Mukesh Gaglia, Jason L |
author_sort | Hedgire, Sandeep S |
collection | PubMed |
description | PURPOSE: To evaluate the time-dependent changes in regional quantitative T2* maps of the kidney following intravenous administration of ferumoxytol. MATERIALS AND METHODS: Twenty-four individuals with normal kidney function underwent T2*-weighted MRI of the kidney before, immediately after, and 48 hours after intravenous administration of ferumoxytol at a dose of 4 mg/kg (group A, n=12) or 6 mg/kg (group B, n=12). T2* values were statistically analyzed using two-tailed paired t-tests. RESULTS: In group A, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.3% and 64.2% for the cortex and 90.8% and 64.6% for the medulla, respectively. In group B, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.2% and 73.4% for the cortex and 94.5% and 74% for the medulla, respectively. This difference was significant for both groups (P<0.0001). CONCLUSION: There is significant and differential uptake of ferumoxytol in the cortex and medulla of physiologically normal kidneys. This differential uptake may offer the ability to interrogate renal cortex and medulla with possible clinical applications in medical renal disease and transplant organ assessment. We propose an organ of interest based dose titration of ferumoxytol to better differentiate circulating from intracellular ferumoxytol particles. |
format | Online Article Text |
id | pubmed-4010631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40106312014-05-08 Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent Hedgire, Sandeep S McDermott, Shaunagh Wojtkiewicz, Gregory R Abtahi, Seyed Mahdi Harisinghani, Mukesh Gaglia, Jason L Int J Nanomedicine Original Research PURPOSE: To evaluate the time-dependent changes in regional quantitative T2* maps of the kidney following intravenous administration of ferumoxytol. MATERIALS AND METHODS: Twenty-four individuals with normal kidney function underwent T2*-weighted MRI of the kidney before, immediately after, and 48 hours after intravenous administration of ferumoxytol at a dose of 4 mg/kg (group A, n=12) or 6 mg/kg (group B, n=12). T2* values were statistically analyzed using two-tailed paired t-tests. RESULTS: In group A, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.3% and 64.2% for the cortex and 90.8% and 64.6% for the medulla, respectively. In group B, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.2% and 73.4% for the cortex and 94.5% and 74% for the medulla, respectively. This difference was significant for both groups (P<0.0001). CONCLUSION: There is significant and differential uptake of ferumoxytol in the cortex and medulla of physiologically normal kidneys. This differential uptake may offer the ability to interrogate renal cortex and medulla with possible clinical applications in medical renal disease and transplant organ assessment. We propose an organ of interest based dose titration of ferumoxytol to better differentiate circulating from intracellular ferumoxytol particles. Dove Medical Press 2014-04-28 /pmc/articles/PMC4010631/ /pubmed/24812510 http://dx.doi.org/10.2147/IJN.S61460 Text en © 2014 Hedgire et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Hedgire, Sandeep S McDermott, Shaunagh Wojtkiewicz, Gregory R Abtahi, Seyed Mahdi Harisinghani, Mukesh Gaglia, Jason L Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent |
title | Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent |
title_full | Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent |
title_fullStr | Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent |
title_full_unstemmed | Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent |
title_short | Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent |
title_sort | evaluation of renal quantitative t2* changes on mri following administration of ferumoxytol as a t2* contrast agent |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010631/ https://www.ncbi.nlm.nih.gov/pubmed/24812510 http://dx.doi.org/10.2147/IJN.S61460 |
work_keys_str_mv | AT hedgiresandeeps evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent AT mcdermottshaunagh evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent AT wojtkiewiczgregoryr evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent AT abtahiseyedmahdi evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent AT harisinghanimukesh evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent AT gagliajasonl evaluationofrenalquantitativet2changesonmrifollowingadministrationofferumoxytolasat2contrastagent |